Author

Jimit Lakhani

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Aaron D. Richardson· 1 shared Alejandro HochkoeppleriD· 1 shared Alessandra StefaniD· 1 shared Alex K. ShalekiD· 1 shared Andras BoeszoermenyiiD· 1 shared Anthony C. VarcaiD· 1 shared Bin Hu· 1 shared Christoph GorgullaiD· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Aaron D. Richardson

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Expanding the HDAC druggable landscape beyond enzymatic activity

Julien Olivet, Soon Gang Choi, Salvador Sierra, Tina M. O’Grady, Mario de la Fuente Revenga, Florent Laval, Vladimir V. Botchkarev, Christoph Gorgulla, Paul W. Coote, Jérémy Blavier, Ezekiel A. Geffken, Jimit Lakhani, Kijun Song, Zoe C. Yeoh, Bin Hu, , Marc Vidal

This paper identifies a non-enzymatic HDAC inhibitor with anti-tumor and anti-psychedelic effects, showing reduced gene modulation compared to enzymatic inhibitors.

bioRxiv · Dec 7, 2022 · PreprintMolecular Biology